Twist Bioscience (TWST) Reports Q1 Loss, Misses Revenue Estimates

分组1 - Twist Bioscience reported a quarterly loss of $0.5 per share, which was worse than the Zacks Consensus Estimate of a loss of $0.48, and an improvement from a loss of $0.53 per share a year ago, indicating a surprise of -5.26% [1] - The company generated revenues of $103.7 million for the quarter ended December 2025, slightly missing the Zacks Consensus Estimate by 0.05%, but showing growth from $88.71 million in the same quarter last year [2] - Over the last four quarters, Twist Bioscience has surpassed consensus revenue estimates three times, but only once for EPS estimates [2] 分组2 - The stock has increased by approximately 29.5% since the beginning of the year, significantly outperforming the S&P 500's gain of 1.4% [3] - The company's earnings outlook is crucial for future stock performance, with current consensus EPS estimates at -$0.46 for the coming quarter and -$1.64 for the current fiscal year [7] - The Medical - Biomedical and Genetics industry, to which Twist Bioscience belongs, is currently ranked in the top 39% of over 250 Zacks industries, suggesting a favorable environment for stock performance [8]